安必平收盘下跌2.82%，滚动市盈率1327.72倍，总市值29.71亿元

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Anbiping, a company in the medical device industry, which is currently facing significant challenges reflected in its high PE ratio and declining revenues [1][2] - Anbiping's closing stock price is 31.75 yuan, with a PE ratio of 1327.72, significantly higher than the industry average of 54.56 and the median of 37.54 [1][2] - The company's total market capitalization is 2.971 billion yuan, ranking it 122nd in the industry based on PE ratio [1][2] Group 2 - As of March 31, 2025, Anbiping has 10,309 shareholders, an increase of 4,393 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - Anbiping's main business includes tumor screening and diagnostic reagents, automation equipment, and auxiliary diagnostic AI software [1] - In the latest quarterly report for Q1 2025, the company reported revenue of 72.54 million yuan, a year-on-year decrease of 28.51%, and a net loss of approximately 11.06 million yuan, a year-on-year decline of 238.49%, with a gross profit margin of 61.97% [1]